IL163958A0 - Anxiolytic agents with reduced sedative and ataxideffects - Google Patents

Anxiolytic agents with reduced sedative and ataxideffects

Info

Publication number
IL163958A0
IL163958A0 IL16395803A IL16395803A IL163958A0 IL 163958 A0 IL163958 A0 IL 163958A0 IL 16395803 A IL16395803 A IL 16395803A IL 16395803 A IL16395803 A IL 16395803A IL 163958 A0 IL163958 A0 IL 163958A0
Authority
IL
Israel
Prior art keywords
ataxideffects
anxiolytic agents
reduced sedative
sedative
reduced
Prior art date
Application number
IL16395803A
Other languages
English (en)
Original Assignee
Wisys Technology Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisys Technology Foundation filed Critical Wisys Technology Foundation
Publication of IL163958A0 publication Critical patent/IL163958A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL16395803A 2002-03-28 2003-03-28 Anxiolytic agents with reduced sedative and ataxideffects IL163958A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36840802P 2002-03-28 2002-03-28
PCT/US2003/009587 WO2003082832A2 (en) 2002-03-28 2003-03-28 Anxiolytic agents with reduced sedative and ataxic effects

Publications (1)

Publication Number Publication Date
IL163958A0 true IL163958A0 (en) 2005-12-18

Family

ID=28675480

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16395803A IL163958A0 (en) 2002-03-28 2003-03-28 Anxiolytic agents with reduced sedative and ataxideffects

Country Status (16)

Country Link
US (6) US7119196B2 (enExample)
EP (1) EP1490344B1 (enExample)
JP (1) JP2005525392A (enExample)
KR (2) KR20080060286A (enExample)
CN (1) CN1642924A (enExample)
AT (1) ATE389640T1 (enExample)
AU (1) AU2003230754B2 (enExample)
BR (1) BR0308918A (enExample)
CA (1) CA2480869A1 (enExample)
DE (1) DE60319812T2 (enExample)
DK (1) DK1490344T3 (enExample)
ES (1) ES2300576T3 (enExample)
IL (1) IL163958A0 (enExample)
MX (1) MXPA04009332A (enExample)
NZ (1) NZ535517A (enExample)
WO (1) WO2003082832A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47475E1 (en) * 2002-03-28 2019-07-02 Wisys Technology Foundation, Inc. Selective agents for pain suppression
AU2005260650A1 (en) 2004-06-30 2006-01-12 Wisys Technology Foundation, Inc. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US8119629B2 (en) * 2007-10-03 2012-02-21 Bristol-Meyers Squibb Company Carboxamide GABAA α2 modulators
TWI422369B (zh) * 2008-01-22 2014-01-11 Lilly Co Eli κ選擇性類鴉片受體拮抗劑
US20100261711A1 (en) * 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
JP2013209292A (ja) * 2010-07-23 2013-10-10 Nippon Chemiphar Co Ltd P2x4受容体拮抗剤
US9006233B2 (en) 2011-04-28 2015-04-14 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2885148A1 (en) 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
FR3010785B1 (fr) * 2013-09-18 2015-08-21 Snecma Procede de controle de la densite d'energie d'un faisceau laser par analyse d'image et dispositif correspondant
CA3012791C (en) 2016-01-27 2024-01-23 Universitat Zurich Use of gabaa receptor modulators for treatment of itch
SI3439665T1 (sl) 2016-03-18 2023-05-31 Uwm Research Foundation, Inc. Zdravljenje kognitivnih simptomov in simptomov razpoloženja pri nevrodegenerativnih in nevropsihiatričnih motnjah z agonisti receptorja GABAA, ki vsebujejo ALFA5
CA3033964A1 (en) 2016-08-16 2018-02-22 Uwm Research Foundation, Inc. Gaba(a) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma
JP7139323B2 (ja) * 2016-11-01 2022-09-20 エフ.ホフマン-ラ ロシュ アーゲー Cns関連疾患を処置するための1,3-ジヒドロ-1,4-ベンゾジアゼピン-2-チオン
CN107056760A (zh) * 2017-01-22 2017-08-18 苏州楚凯药业有限公司 5,7位取代的1H‑苯并[e][1,4]二氮杂‑2(3H)‑酮衍生物的制备方法
CN107216332B (zh) * 2017-06-29 2019-04-30 上海药明康德新药开发有限公司 叔丁基-7-羟甲基-7,8-二氢4h吡唑并二氮杂卓5(6h)甲酸基酯的合成方法
CN107325101B (zh) * 2017-06-29 2019-03-26 上海合全药物研发有限公司 6-羟甲基-6,7-二氢-5h,9h-咪唑并二氮杂卓-8-羧酸叔丁酯的合成方法
US20200316087A1 (en) 2017-10-03 2020-10-08 Uwm Research Foundation, Inc. Novel combination therapy for anxiety disorders, epilepsy, and pain
CN115380034A (zh) 2020-03-31 2022-11-22 豪夫迈·罗氏有限公司 作为GABA Aγ1 PAM的苯并二氮杂䓬衍生物
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AR127127A1 (es) * 2021-09-24 2023-12-20 Hoffmann La Roche NUEVOS DERIVADOS DE PIRIDODIAZEPINAS COMO PAM DE GABAA g1
EP4408848B1 (en) 2021-09-29 2025-11-05 F. Hoffmann-La Roche AG Benzodiazepine derivatives as gaba a gamma1 positive allosteric modulators
JP2024536393A (ja) 2021-10-06 2024-10-04 エフ. ホフマン-ラ ロシュ アーゲー GABA A γ1受容体のポジティブアロステリックモジュレーターとしてのベンゾジアゼピン誘導体
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
JP2025508069A (ja) 2022-03-07 2025-03-21 ヤンセン ファーマシューティカルズ,インコーポレーテッド アチカプラントを含む組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2893992A (en) 1959-07-07 I ii i i
US3886141A (en) * 1971-10-07 1975-05-27 Hoffmann La Roche Preparation of 5-pyridyl benzodiazepine utilizing hexamethylenetetramine
US4440685A (en) * 1974-09-11 1984-04-03 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
US4280957A (en) 1974-09-11 1981-07-28 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
US4401597A (en) 1978-05-15 1983-08-30 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
DE3435973A1 (de) * 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
ES2037013T3 (es) * 1986-01-21 1993-06-16 Boehringer Ingelheim Kg Procedimiento para preparar tieno-1,4-diazepinas.
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
US5968176A (en) * 1997-05-29 1999-10-19 3Com Corporation Multilayer firewall system
CZ20033003A3 (cs) 2001-04-12 2004-05-12 F@Áhoffmann@Laárocheáag Dihydrobenzo [b][�Ź@]diazepin@onové deriváty jako MGLUR@ antagonisty II
US7161904B2 (en) * 2002-06-04 2007-01-09 Fortinet, Inc. System and method for hierarchical metering in a virtual router based network switch
US7415723B2 (en) * 2002-06-11 2008-08-19 Pandya Ashish A Distributed network security system and a hardware processor therefor

Also Published As

Publication number Publication date
US20070049580A1 (en) 2007-03-01
EP1490344B1 (en) 2008-03-19
ATE389640T1 (de) 2008-04-15
DK1490344T3 (da) 2008-06-16
CN1642924A (zh) 2005-07-20
US20070054881A1 (en) 2007-03-08
US20070299058A1 (en) 2007-12-27
NZ535517A (en) 2007-02-23
BR0308918A (pt) 2005-01-04
DE60319812T2 (de) 2009-04-23
JP2005525392A (ja) 2005-08-25
US20100130481A1 (en) 2010-05-27
AU2003230754B2 (en) 2007-10-25
US20080108605A1 (en) 2008-05-08
KR100865410B1 (ko) 2008-10-24
ES2300576T3 (es) 2008-06-16
EP1490344A2 (en) 2004-12-29
KR20080060286A (ko) 2008-07-01
DE60319812D1 (de) 2008-04-30
US7119196B2 (en) 2006-10-10
KR20040098029A (ko) 2004-11-18
WO2003082832A2 (en) 2003-10-09
MXPA04009332A (es) 2005-12-12
CA2480869A1 (en) 2003-10-09
AU2003230754A1 (en) 2003-10-13
WO2003082832A3 (en) 2004-04-08
US20040082573A1 (en) 2004-04-29
US7235656B2 (en) 2007-06-26

Similar Documents

Publication Publication Date Title
IL163958A0 (en) Anxiolytic agents with reduced sedative and ataxideffects
SI1660095T1 (sl) Triciklični parp inhibitorji
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
WO2002044183A3 (en) Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
MA27343A1 (fr) 1-amino triazolo [4,3-a] quinazoline-5-ones et/ou -5-thiones inhibitrices de phosphodiesterases iv.
MX2009000404A (es) Sales de benzodiazepina de accion corta y sus formas polimorficas.
CA2400554A1 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
MY145722A (en) Diazabicyclic central nervous system active agents
ZA200108204B (en) Cyclo-alkyl substituted benzimidazoles and their use as PARP inhibitors.
DK1185529T3 (da) Pyrazolbenzodiazepiner som CDK2-inhibitorer
DK1430057T3 (da) Substituerede 2-pyridinyl-6,7,8, 9-tetrahydropyrimido [1,2-a] pyrimidin-4-on- og 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivater
DK1315731T3 (da) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on og 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)on-derivater
EE05433B1 (et) 4-(2-butlamino)-2,7-dimetl-8-(2-metl-6-metoksprid-3-l)[1,5-a]prasolo-1,3,5-triasiin, selle farmatseutiliselt vastuv?etavad eelravimid v?i farmatseutiliselt vastuv?etavad soolad ning nende kasutamine
DK1109810T3 (da) Benzonaphthydin-N-oxider med PDE3- og PDE4-inhiberende aktivitet
MX2007005478A (es) Formulaciones de derivados de [1,4]diazepino[6,7,1-ij]quinolina.
DK1480981T3 (da) 1-(Alkyl)-, 1-(heteroaryl)alkyl- og 1-[(aryl)alkyl]-7-(pyrimidin-4-yl) imidazo[1,2a]pyrimidin-5(1H)-onderivater
MY136822A (en) Derivatives of [6, 7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of cams and leukointegrins
GB0613693D0 (en) Benzodiazepine salts (3)
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
DE60319802D1 (de) Sedierende nicht-benzodiazepin-formulierungen
PT1212119E (pt) Utilizacao de ciamemazina no tratamento do desmame subito de benzodiazepinas
DK0937075T3 (da) Hidtil ukendte imidazo- og oxazolopyridiner som phosphodiesteraseinhibitorer
HK1073463A (en) Anxiolytic agents with reduced sedative and ataxic effects
TR200000473T1 (tr) Adenozin reseptörüne bağlılık gösteren antikonvülsif ve antialerjik/antiastımatik pirazolo-[3,4-d] pirimidinler ve bunları hazırlama yöntemi.